Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.46−1.23 (-2.69%)
Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –
Rigel Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Rigel Pharmaceuticals's total assets was $523.88M at Sep 30, 2026. For fiscal 2025 it was $513.59M, up 213.2% from the year before. Over ten years it grew 14.6% a year on average. The highest annual figure on record is $513.59M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $513.59M | +213.2% |
| FY2024 | Dec 31, 2024 | $163.98M | +39.9% |
| FY2023 | Dec 31, 2023 | $117.23M | -12.7% |
| FY2022 | Dec 31, 2022 | $134.28M | -19.8% |
| FY2021 | Dec 31, 2021 | $167.33M | +51.6% |
| FY2020 | Dec 31, 2020 | $110.38M | -25.2% |
| FY2019 | Dec 31, 2019 | $147.57M | +6.1% |
| FY2018 | Dec 31, 2018 | $139.11M | +16.8% |
| FY2017 | Dec 31, 2017 | $119.11M | +52.4% |
| FY2016 | Dec 31, 2016 | $78.13M | -40.7% |
| FY2015 | Dec 31, 2015 | $131.75M | -14.5% |
| FY2014 | Dec 31, 2014 | $154.14M | -31.8% |
| FY2013 | Dec 31, 2013 | $226.06M | -27.1% |
| FY2012 | Dec 31, 2012 | $310.04M | +20.6% |
| FY2011 | Dec 31, 2011 | $257.11M | +37.7% |
| FY2010 | Dec 31, 2010 | $186.70M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $523.88M | +116.0% |
| Q2 FY2026 | Jun 30, 2026 | $521.07M | +152.0% |
| Q1 FY2026 | Mar 31, 2026 | $504.61M | +186.8% |
| Q4 FY2025 | Dec 31, 2025 | $513.59M | +213.2% |
| Q3 FY2025 | Sep 30, 2025 | $242.53M | +74.0% |
| Q2 FY2025 | Jun 30, 2025 | $206.74M | +61.0% |
| Q1 FY2025 | Mar 31, 2025 | $175.97M | +39.1% |
| Q4 FY2024 | Dec 31, 2024 | $163.98M | +39.9% |
| Q3 FY2024 | Sep 30, 2024 | $139.42M | +20.9% |
| Q2 FY2024 | Jun 30, 2024 | $128.41M | +9.7% |
| Q1 FY2024 | Mar 31, 2024 | $126.52M | +2.4% |
| Q4 FY2023 | Dec 31, 2023 | $117.23M | -12.7% |
| Q3 FY2023 | Sep 30, 2023 | $115.32M | -0.2% |
| Q2 FY2023 | Jun 30, 2023 | $117.09M | -8.5% |
| Q1 FY2023 | Mar 31, 2023 | $123.61M | -17.1% |
| Q4 FY2022 | Dec 31, 2022 | $134.28M | -19.8% |
| Q3 FY2022 | Sep 30, 2022 | $115.61M | -38.0% |
| Q2 FY2022 | Jun 30, 2022 | $128.00M | -36.5% |
| Q1 FY2022 | Mar 31, 2022 | $149.07M | -31.0% |
| Q4 FY2021 | Dec 31, 2021 | $167.33M | +51.6% |
| Q3 FY2021 | Sep 30, 2021 | $186.52M | +51.6% |
| Q2 FY2021 | Jun 30, 2021 | $201.60M | +46.0% |
| Q1 FY2021 | Mar 31, 2021 | $215.99M | +50.7% |
| Q4 FY2020 | Dec 31, 2020 | $110.38M | -25.2% |
| Q3 FY2020 | Sep 30, 2020 | $123.06M | -21.1% |
| Q2 FY2020 | Jun 30, 2020 | $138.04M | -11.6% |
| Q1 FY2020 | Mar 31, 2020 | $143.36M | -17.0% |
| Q4 FY2019 | Dec 31, 2019 | $147.57M | +6.1% |
| Q3 FY2019 | Sep 30, 2019 | $156.06M | +26.7% |
| Q2 FY2019 | Jun 30, 2019 | $156.16M | +10.6% |
| Q1 FY2019 | Mar 31, 2019 | $172.78M | +74.9% |
| Q4 FY2018 | Dec 31, 2018 | $139.11M | +16.8% |
| Q3 FY2018 | Sep 30, 2018 | $123.17M | +72.9% |
| Q2 FY2018 | Jun 30, 2018 | $141.22M | +65.2% |
| Q1 FY2018 | Mar 31, 2018 | $98.81M | -2.5% |
| Q4 FY2017 | Dec 31, 2017 | $119.11M | +52.4% |
| Q3 FY2017 | Sep 30, 2017 | $71.25M | – |
| Q2 FY2017 | Jun 30, 2017 | $85.48M | – |
| Q1 FY2017 | Mar 31, 2017 | $101.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $78.13M | – |
See a number that looks wrong?